New Investigator Research Grant Program

Complex karyotype acute myeloid leukemia (CK-AML) is an aggressive blood cancer that is highly resistant to current treatments and often fatal. It is marked by widespread chromosome abnormalities and frequent mutations in the TP53 gene, a key tumor suppressor. Despite advances in therapy, most patients relapse because some cancer cells survive treatment and drive disease recurrence. Our research shows that CK-AML is made up of different types of cancer cells, including a population that resembles immature red blood cell precursors (erythroid cells). These erythroid-like cancer cells are especially resistant to therapy and can regenerate the disease after treatment. We aim to understand how these resistant cells arise and survive. Using patient samples, advanced imaging, and specialized laboratory models, we will identify the genes and molecular pathways that allow these cells to evade treatment. We will also test new strategies to eliminate them, including targeting a protein called TRIM28 that helps maintain their resistant state. This work seeks to uncover the root causes of treatment resistance in CK-AML and develop more effective therapies that prevent relapse. Ultimately, our goal is to improve survival and quality of life for patients facing this devastating disease.